Press Releases March 30, 2026

HeartCore Reports Full Year 2025 Results

HeartCore Enterprises reports strategic transformation and full year 2025 financial results with net income of $5.5 million driven by divestiture gains and focus shift to financial services.

By Derek Hwang HTCR
HeartCore Reports Full Year 2025 Results
HTCR

HeartCore Enterprises, Inc., a Tokyo-based IPO consulting services company listed on Nasdaq (HTCR), announced its full year 2025 results. The company reported revenues of $9.0 million, gross profit of $3.2 million, and net income of $5.5 million compared to a net loss last year. The positive net income was primarily due to gains from the divestiture of its software subsidiary and strategic shift toward financial services and capital markets activities. HeartCore authorized a one-time stockholder distribution and a $2.0 million share repurchase program. The company is actively engaged with 16 Go IPO clients, including 6 progressing toward U.S. exchange listings, with a new subsidiary, Higgs Field, established to support the financial services transition.

Key Points

  • HeartCore divested its software business subsidiary and is shifting focus to financial services and capital markets advisory.
  • Reported net income of $5.5 million in 2025 driven by divestiture gains and operational cost reductions despite revenue decline.
  • Authorized one-time distribution to shareholders and a $2 million share repurchase program signaling confidence in shareholder value.
  • The company is working with 16 clients on IPO processes, 6 of which are preparing for U.S. exchange listings, indicating growth potential in U.S. capital markets advisory.

NEW YORK and TOKYO, March 31, 2026 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, reported financial results for the full year ended December 31, 2025.

Recent Operational Highlights

  • As of March 31, 2026, HeartCore was engaged with 16 Go IPO clients, including 6 clients currently in various stages of preparation for potential public registrations and U.S. exchange listings.
  • Authorized one-time distribution payment to stockholders.
  • Authorized $2.0 million share repurchase program.
  • Divested software business subsidiary, HeartCore Co., Ltd (“HeartCore Japan”).
  • Established Higgs Field Co., Ltd. (“Higgs Field”) on October 31, 2025, as a new subsidiary in Japan to support the Company’s strategic transition toward financial services.

Management Commentary

HeartCore CEO Sumitaka Kanno commented:“Over the past year, we executed a strategic transformation of our business, including the divestiture of our software business subsidiary, HeartCore Japan, and a shift toward financial services and capital markets-related activities. We have also made progress in our Go IPO business, with an expanding client base and multiple engagements advancing through various stages of the registration and listing process. In addition, we established Higgs Field in the fourth quarter of 2025 to serve as our new operating platform in Japan. Going forward, we will continue to strengthen our focus on financial services and aim to drive sustainable growth and long-term stockholder value.”

Full Year 2025 Financial Results
Revenues were $9.0 million, compared to $22.7 million in the same period last year. The decrease was primarily due to receipt of $13 million in warrant revenue from one large Go IPO deal in the prior period, and no comparable revenue in the current period.

Gross profit was $3.2 million, compared to $14.7 million in the same period last year. The decrease was primarily due to the absence of a significant warrant-related revenue contribution from a large Go IPO deal recognized in the prior period.

Operating expenses decreased to $6.3 million, compared to $14.9 million in the same period last year. The decrease was primarily due to the reduction in operating expenses to save cash flows and the absence of impairment charges for intangible assets and goodwill during the current period.

Net income was $5.5 million, compared to a net loss of $5.2 million in the same period last year. The increase was primarily due to the gain on the sale of HeartCore Japan.

Adjusted EBITDA was $6.5 million, compared to $7.3 million in the same period last year.

As of December 31, 2025, the Company had cash and cash equivalents of $2.0 million.

About HeartCore Enterprises, Inc.
HeartCore Enterprises, Inc. is headquartered in Tokyo, Japan, and is a leading consulting services company providing U.S. market listing support and related advisory services primarily to Japanese corporate clients. For more information, please visit https://heartcore-enterprises.com/.

Non-GAAP Financial Measures
This document includes references to adjusted EBITDA, which is a non-GAAP financial measure. For the purposes of this presentation, adjusted EBITDA is calculated by adjusting net loss to exclude depreciation and amortization, changes in fair value of investments in marketable securities, changes in fair value of investment in warrants, interest income, and interest expenses.

This measure is presented as supplemental information and is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).

Management believes that adjusted EBITDA provides useful information to investors by highlighting the Company’s core operational performance, excluding non-cash and non-recurring items. However, non-GAAP financial measures have limitations and should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP.

ItemFY25FY24Net income (loss)$5.5 million$(5.2) million(+) Depreciation$0.0 million$0.1 million(+) Impairment loss on goodwill$0.0 million$3.3 million(+) Impairment loss on intangible assets$0.0 million$3.9 million(+) Changes in fair value of investments in marketable securities$1.5 million$2.4 million(+) Changes in fair value of investment in warrants$(0.6) million$(1.7) million(+) Loss on sale of warrants$0.0 million$4.0 million(+) Impairment of investment in equity securities$0.0 million$0.3 million(+) Changes in fair value of derivative liability$(0.1) million$0.0 million(+) Loss on forgiveness of note receivable$0.1 million$0.1 million(+) Interest income$(0.0) million$(0.0) million(+) Interest expenses$0.1 million$0.1 millionAdjusted EBITDA$6.5 million$7.3 million


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believed,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue,” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in HeartCore’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond HeartCore’s control which could, and likely will materially affect actual results, and levels of activity, performance, or achievements. Any forward-looking statement reflects HeartCore’s current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. HeartCore assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

HeartCore Investor Relations Contact:
Gateway Group, Inc.
John Yi and Steven Shinmachi
[email protected]
(949) 574-3860

HeartCore Enterprises, Inc.Consolidated Balance Sheets        December 31,
  December 31,  2025
  2024
      ASSETSCurrent assets:     Cash and cash equivalents$1,985,962  $1,973,810 Accounts receivable 707,865   1,030,243 Investments in marketable securities 3,690,187   4,495,703 Prepaid expenses 182,077   131,325 Current portion of long-term note receivable 100,000   100,000 Deferred offering costs 250,000   - Other current assets 208,503   136,217 Current assets of discontinued operations -   1,550,067 Proceeds receivable from sale of discontinued operations 1,291,298   - Total current assets 8,415,892   9,417,365       Non-current assets:     Property and equipment, net 291,589   475,697 Operating lease right-of-use assets 29,449   172,594 Long-term investment in warrants 280,924   577,786 Long-term note receivable -   100,000 Deferred tax assets 23,121   31,575 Security deposits 282,958   108,880 Other non-current assets 549   11,715 Non-current assets of discontinued operations -   3,069,422 Long-term proceeds receivable from sale of discontinued operations 3,736,995   - Total non-current assets 4,645,585   4,547,669       Total assets$13,061,477  $13,965,034       LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:     Accounts payable and accrued expenses$1,146,501  $1,637,108 Accounts payable and accrued expenses - related party 124,618   47,199 Accrued payroll and other employee costs 509,547   273,115 Due to related party 285   885 Short-term debt - related party 75,000   75,000 Current portion of long-term debts 50,598   46,382 Insurance premium financing 13,430   16,626 Factoring liability 135,982   172,394 Operating lease liabilities, current 32,793   134,910 Finance lease liabilities, current -   15,956 Income tax payables 1,857,386   818,030 Deferred revenue 676,216   751,251 Derivative liability 121,719   - Other current liabilities 586,175   589,762 Current liabilities of discontinued operations -   2,843,104 Total current liabilities 5,330,250   7,421,722       Non-current liabilities:     Long-term debts 448,376   498,706 Operating lease liabilities, non-current -   41,530 Finance lease liabilities, non-current -   43,593 Asset retirement obligations -   72,463 Non-current liabilities of discontinued operations -   2,425,005 Total non-current liabilities 448,376   3,081,297       Total liabilities 5,778,626   10,503,019       Shareholders' equity:     Preferred shares, $0.0001 par value, 20,000,000 shares authorized; Series A convertible preferred shares, 4,000 and no shares designated, 1,017 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of $1,158,362 and nil as of December 31, 2025 and 2024, respectively 691,858   - Common shares, $0.0001 par value, 200,000,000 shares authorized, 25,419,807 and 21,937,987 shares issued and outstanding as of December 31, 2025 and 2024, respectively 2,542   2,193 Subscription receivable -   (103,942)Additional paid-in capital 21,899,754   20,656,153 Accumulated deficit (13,755,534)  (16,244,843)Accumulated other comprehensive income (loss) (58,497)  343,936 Total HeartCore Enterprises, Inc. shareholders' equity 8,780,123   4,653,497 Non-controlling interests (1,497,272)  (1,191,482)Total shareholders' equity 7,282,851   3,462,015       Total liabilities and shareholders' equity$13,061,477  $13,965,034       



HeartCore Enterprises, Inc.Consolidated Statements of Operations and Comprehensive Income (Loss)        For the Years Ended December 31,  2025
  2024
      Revenues$8,968,732  $22,685,544 Cost of revenues (including cost of revenues resulting from transactions with a related party of $261,257 and $160,502 for the years ended December 31, 2025 and 2024, respectively) 5,817,279   7,969,898 Gross profit 3,151,453   14,715,646       Operating expenses:     Selling expenses 233,744   621,070 General and administrative expenses (including general and administrative expenses resulting from transactions with a related party of $29,048 and $41,786 for the years ended December 31, 2025 and 2024, respectively) 6,039,026   6,921,959 Research and development expenses -   179,762 Impairment of intangible asset -   3,878,125 Impairment of goodwill -   3,276,441 Total operating expenses 6,272,770   14,877,357       Loss from continuing operations (3,121,317)  (161,711)      Other income (expenses):     Changes in fair value of investments in marketable securities (1,494,234)  (2,412,385)Changes in fair value of investments in warrants 625,675   1,657,699 Loss on sale of warrants -   (3,970,628)Impairment of investment in equity securities -   (300,000)Changes in fair value of derivative liability 114,422   - Loss on forgiveness of note receivable (100,000)  (100,000)Interest income 5,381   15,882 Interest expenses (87,660)  (118,789)Other income 100,233   32,042 Other expenses (181,605)  (153,917)Total other expenses (1,017,788)  (5,350,096)      Loss from continuing operations before income tax expense (benefit)(4,139,105)  (5,511,807)      Income tax expense (benefit) 44,900   (363,156)      Net loss from continuing operations (4,184,005)  (5,148,651)Income (loss) from discontinued operations, net of income tax 9,677,293   (64,249)Net income (loss) 5,493,288   (5,212,900)Less: net loss attributable to non-controlling interests (300,596)  (3,731,526)Net income (loss) attributable to HeartCore Enterprises, Inc. 5,793,884   (1,481,374)Dividends accrued on Series A convertible preferred shares (94,357)  - Net income (loss) attributable to HeartCore Enterprises, Inc. common shareholders$5,699,527  $(1,481,374)      Other comprehensive loss:     Foreign currency translation adjustment (152,969)  (16,614)      Total comprehensive income (loss) 5,340,319   (5,229,514)Less: comprehensive loss attributable to non-controlling interests (305,790)  (3,760,195)Comprehensive income (loss) attributable to HeartCore Enterprises, Inc.$5,646,109  $(1,469,319)      Net income (loss) from continuing operations attributable to HeartCore Enterprises, Inc. per common share     Basic$(0.17) $(0.07)Diluted$(0.17) $(0.07)      Income (loss) from discontinued operations per common share     Basic$0.42  $(0.00)Diluted$0.38  $(0.00)      Net income (loss) attributable to HeartCore Enterprises, Inc. per common share   Basic$0.25  $(0.07)Diluted$0.22  $(0.07)      Weighted average common shares outstanding     Basic 23,072,519   20,940,956 Diluted 25,459,388   20,940,956 



HeartCore Enterprises, Inc.Consolidated Statements of Cash Flows        For the year ended December 31,  2025
  2024
      Cash flows from operating activities of continuing operations:     Net income$5,493,288  $(5,212,900)Income from discontinued operations, net of income tax 9,677,293   (64,249)Net loss from continuing operations (4,184,005)  (5,148,651)Adjustments to reconcile net loss from continuing operations to net cash flows   used in operating activities of continuing operations:     Depreciation and amortization expenses 46,373   676,047 Loss on disposal of property and equipment 116,981   1,798 Non-cash lease expense 62,845   126,217 Gain on termination of lease (9,059)  - Impairment of intangible asset -   3,878,125 Impairment of goodwill -   3,276,441 Deferred income taxes 9,192   (1,297,495)Stock-based compensation (151,139)  368,744 Marketable securities received as noncash consideration -   (572,010)Warrants received as noncash consideration (837,913)  (12,969,683)Changes in fair value of investments in marketable securities 1,494,234   2,412,385 Changes in fair value of investment in warrants (625,675)  (1,657,699)Loss on sale of warrants -   3,970,628 Impairment of investment in equity securities -   300,000 Impairment of investment in SAFE -   75,000 Changes in fair value of derivative liability (114,422)  - Loss on forgiveness of note receivable 100,000   100,000 Gain on settlement of asset retirement obligations (45,873)  - Changes in assets and liabilities:     Accounts receivable 322,040   1,050,522 Prepaid expenses 86,563   178,949 Other assets (119,413)  71,469 Accounts payable and accrued expenses (485,665)  318,803 Accounts payable and accrued expenses - related party 79,600   47,955 Accrued payroll and other employee costs 234,835   (59,033)Due to related party (585)  - Operating lease liabilities (54,400)  (131,935)Income tax payables 1,036,456   667,483 Deferred revenue (75,035)  (98,145)Other liabilities (3,036)  523,768 Net cash flows used in operating activities of continuing operations (3,117,101)  (3,890,317)      Cash flows from investing activities of continuing operations:     Purchase of investment in SAFE -   (75,000)Net proceeds from sale of warrants -   5,640,000 Proceeds from sale of marketable securities 1,071,732   749,546 Proceeds from sale of discontinued operations, net of cash divested 4,518,868   - Net cash flows provided by investing activities of continuing operations 5,590,600   6,314,546       Cash flows from financing activities of continuing operations:     Payments for finance lease (14,666)  (16,518)Proceeds from related party debt -   75,000 Repayment of long-term debts (46,114)  (33,919)Repayment of insurance premium financing (142,696)  (156,063)Net repayment of factoring arrangement (36,412)  (390,373)Capital contribution from non-controlling shareholder -   67,195 Dividends paid for common shares (3,304,575)  (834,566)Proceeds from issuance of common shares related to at the market offering agreement 30,445   1,423,342 Proceeds from collection of subscription receivable 103,942   - Proceeds from exercise of stock options 117,000   - Proceeds from issuance of Series A convertible preferred shares and common shares related to securities purchase agreement, net of share issuance costs 1,800,000   - Net cash flows provided by (used in) financing activities of continuing operations (1,493,076)  134,098       Cash flows from discontinued operations:     Net cash flows used in operating activities of discontinued operations (854,831)  (884,654)Net cash flows provided by investing activities of discontinued operations 171,641   34,658 Net cash flows used in financing activities of discontinued operations (351,089)  (452,744)Net cash flows used in discontinued operations (1,034,279)  (1,302,740)      Effect of exchange rate changes (81,271)  (146,977)      Net change in cash and cash equivalents (135,127)  1,108,610       Cash and cash equivalents - beginning of the year 2,121,089   1,012,479       Cash and cash equivalents - end of the year$1,985,962  $2,121,089       Supplemental cash flow disclosures:     Interest paid$109,440  $143,101 Income taxes paid$211,844  $298,466       Non-cash investing and financing transactions:     Insurance premium financing$139,500  $172,689 Warrants converted to marketable securities$1,760,450  $6,443,276 Issuance of common shares related to equity purchase agreement$250,000  $- Dividends accrued on Series A convertible preferred shares$94,357  $- Issuance of common shares for dividends on Series A convertible preferred shares$220,000  $- Series A convertible preferred shares converted to common shares$668,728  $- 

Risks

  • Revenue decline due to the lack of comparable warrant-related income which contributed significantly to last year's revenues, creating revenue predictability risk.
  • Reliance on successful execution of strategic transformation toward financial services, which may involve operational and market risks during transition.
  • Potential uncertainties due to exposure to market fluctuations, regulatory changes in U.S. listings, and currency translation impacts as HeartCore operates internationally affecting future financial results.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026